Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, +27

New England Journal of Medicine

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, +21

Science

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley, +23

Nature

MedicineImmunologyTumor ImmunityAutoimmunityImmunomodulation +4

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, +19

Nature

MedicineBiomarker TargetAnti-pd-l1 Antibody Mpdl3280aImmunologyPathology +8

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Haidong Dong, Scott E. Strome, Diva R. Salomão, +10

Nature Medicine

Immune EvasionCancer ImmunosurveillanceT-cell ApoptosisImmunologyImmunoediting +5

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Alexandra Snyder, Vladimir Makarov, Taha Merghoub, +18

New England Journal of Medicine

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan, +21

New England Journal of Medicine

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid, Caroline Robert, Adil Daud, +23

New England Journal of Medicine

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, +25

The Lancet Oncology

Checkmate 037MedicineMelanomaNivolumab Versus ChemotherapyImmune Checkpoint Inhibitor +7

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

Kaori Sakuishi, Lionel Apétoh, Jenna M. Sullivan, +3

The Journal of Experimental Medicine